Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
RSI CEO Greg Paoli Named Fellow of the Society for Risk Analysis
Risk Sciences International (RSI) is proud to announce that CEO Greg Paoli has been designated as a Fellow of the Society for Risk Analysis (SRA).…
Bias Assessment in Case-Control and Cohort Studies for Hazard Identification
IARC recently published a volume on quantitative bias modelling: Bias assessment in case–control and cohort studies for hazard identification (IARC Scientific Publication No. 171). We…
RSI Helps Strengthen Food Safety Culture in Vietnam
In mid-October 2025, Vietnamese and Canadian experts convened in Đà Nẵng to exchange approaches for strengthening food safety through risk science. The workshop brought together…
Use of Probabilistic Exposure Models in the Assessment of Dietary Exposure to Chemicals
Risk Sciences International CEO, Greg Paoli and RSI senior experts Emma Hartnett and Paul Price, have co-authored a new peer-reviewed publication highlighting the critical role…